Meeting
2023 ASCO Annual Meeting
Clinical activity of mitogen-activated protein kinase (MAPK) inhibitors in patients with MAP2K1 (MEK1)-mutated metastatic cancers: A systematic review and meta-analysis.
Authors
Matthew Dankner
McGill University, Montréal, QC, Canada
Matthew Dankner , Sarah Petrecca , Francois Fabi , Alexander Nowakowski , Charles Vincent Rajadurai , Emmanuelle Rousselle , Andrew Stein , David Jiahua Bian , Peter Tai , Alicia Belaiche , Meredith Li , Anna-Maria Lazaratos , Andrea Quaiattini , Nicola Normanno , Maria E. Arcila , Arielle Elkrief , Marc Ladanyi , April A. N. Rose
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Tissue-Based Biomarkers
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 3125)
DOI
10.1200/JCO.2023.41.16_suppl.3125
Abstract #
3125
Poster Bd #
323
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Investigation of non-V600 BRAF mutations commonly found in NSCLC for their sensitivity to dabrafenib or trametinib.
First Author: Amir Noeparast
Poster
2022 ASCO Annual Meeting
Distinct mutational landscapes characterize melanomas metastatic to different anatomical sites.
First Author: Mahesh Y. Iddawela
Poster
2022 ASCO Annual Meeting
Molecular characterization of NF1-mutated NSCLC and clinical outcomes.
First Author: Christopher Gates
Poster
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Characterization of biomarkers to immune checkpoint blockade therapy across solid tumors.
First Author: Meaghan Russell